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Abstract HIV-associated neurocognitive disorder (HAND),
characterized by a wide spectrum of behavioral, cognitive, and
motor dysfunctions, continues to affect approximately 50% of
HIV(+) patients despite the success of combination antiretro-
viral drug therapy (cART) in the periphery. Of note, potential
toxicity of antiretroviral drugs in the central nervous system
(CNS) remains remarkably underexplored and may contribute
to the persistence of HAND in the cART era. Previous studies
have shown antiretrovirals (ARVs) to be neurotoxic in the
peripheral nervous system in vivo and in peripheral neurons
in vitro. Alterations in lipid and protein metabolism, mito-
chondrial damage, and oxidative stress all play a role in
peripheral ARV neurotoxicity. We hypothesized that ARVs
also induce cellular stresses in the CNS, ultimately leading to
neuronal damage and contributing to the changing clinical and
pathological picture seen in HIV-positive patients in the cART
era. In this report, we show that ARVs are neurotoxic in the
CNS in both pigtail macaques and rats in vivo. Furthermore,
in vitro, ARVs lead to accumulation of reactive oxygen spe-
cies (ROS), and ultimately induction of neuronal damage and
death. Whereas ARVs alone caused some activation of the
endogenous antioxidant response in vitro, augmentation of
this response by a fumaric acid ester, monomethyl fumarate
(MMF), blocked ARV-induced ROS generation, and neuronal
damage/death. These findings implicate oxidative stress as a
contributor to the underlying mechanisms of ARV-induced
neurotoxicity and will provide an access point for adjunctive
therapies to complement ARV therapy and reduce neurotox-
icity in this patient population.
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Introduction
Despite introduction of combination antiretroviral therapy
(cART), HIV-associated neurocognitive disorder (HAND)
continues to affect approximately 50 % of HIV(+) patients
(Dore et al. 1999; Heaton et al. 2010). Furthermore, in the
cART era, the underlying neuropathology has shifted from
overt subcortical involvement to a more insidious cortical
damage (Gannon et al. 2011). Various factors, such as poor
adherence to drug regimen, emergence of resistant virus spe-
cies, and residual viral DNA in the central nervous system
(CNS), may contribute to these changes (Gannon et al. 2011).
However, another likely contributor to HAND in the cARTera
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is the virtually unstudied potential for antiretroviral (ARV)-
related toxicity in the CNS. cART has decreased HIV-related
morbidity and mortality by limiting T cell loss and controlling
opportunistic infections. However, cART regimens are asso-
ciated with potentially serious side effects, including dyslip-
idemia, lipohypertrophy, and increased risk of atherosclerosis
(Vidal et al. 2010). Additionally, cART-associated toxicity in
the peripheral nervous system is well documented, and it is
likely that cART would trigger similar responses in the CNS.
Pharmacokinetic studies suggest limited ARV penetrance into
the CNS and indicate low cerebrospinal fluid (CSF) and
parenchymal drug concentrations (Yilmaz et al. 2004;
Yilmaz et al. 2009). However, direct blood–brain barrier
(BBB) compromise by viral proteins and neuroinflammation
and indirect BBB impairment due to concomitant factors, such
as coexisting infections, can lead to increased CSF and paren-
chymal drug concentrations. Thus, the impact of ARVs in the
CNS of HIV(+) patients is clinically relevant and must be
examined.
Initial cART usually includes two nucleoside/nucleotide
reverse-transcriptase inhibitors (NRTIs) in combination with a
non-nucleoside reverse-transcriptase inhibitor (nNRTI) or with a
protease inhibitor (PI) boosted with a low dose of a second PI,
Ritonavir. NRTIs and nNRTIs bind to the HIV reverse-
transcriptase enzyme and inhibit proviral DNA synthesis; PIs
inhibit viral proteases needed for virus maturation and assembly.
Despite some crossover, certain ARV classes are more highly
associated with particular side effects and toxicities than are
other classes. PIs alter lipid metabolism and induce the endo-
plasmic reticulum stress response in macrophages, linking PIs to
increased risk of atherosclerosis (Touzet and Philips 2010).
NRTIs inhibit DNA polymerase γ and lead to decreased mito-
chondrial DNA, loss of mitochondrial membrane potential, and
oxidative phosphorylation, consequently precipitating oxidative
stress (Nolan and Mallal 2004). Previous studies exploring
possible side effects of ARVs in the CNS are scarce and mostly
involve cell lines (Cui et al. 1997). Given the mutations and
aberrations in immortalized cell lines, these studies may not
reflect the ARV toxicity potentially occurring in biological set-
tings. Peripheral dorsal root ganglia neurons are the only primary
cell type of neural lineage previously studied for ARV toxicity
(Werth et al. 1994). In this report, we examined effects of ARVs
in primary CNS neurons both in vivo and in vitro. Our findings
suggest that cART induces oxidative stress and neurotoxicity in
the CNS, and that the patients on long-term cART regimens
would benefit from adjuvant therapies that include antioxidant
strategies to overcome deleterious effects of cART in the CNS.
Materials and methods
Chemicals and reagents Chemicals and reagents comprise the
following: (1) AIDS Research and Reference Reagent
Program, Division of AIDS, NIAID, NIH, antiretroviral re-
agents; (2) Abcam (Cambridge, MA), mouse monoclonal
NAD(P)H/quinone oxidoreductase-1 (NQO-1) antibody
(A180) and mouse monoclonal synaptophysin antibody
(SY38); (3) BioRad (Hercules, CA), Biosafe Coomassie stain,
immunoblot polyvinylidene fluoride (PVDF) membrane and
prestained broad range molecular weight ladder; (4) Cell
Signaling Technology (Danvers, MA), rabbit polyclonal anti-
body raised against cleaved caspase-3; (5) Citifluor, Ltd.
(London, UK), citifluor AF1. Covance (Princeton, NJ), mouse
monoclonal microtubule-associated protein 2 (MAP2) anti-
body (SMI-52); (6) Dako (Carpinteria, CA), rabbit polyclonal
glial fibrillary acidic protein (GFAP) antibody (Z0334); (7)
Enzo Life Sciences (Farmingdale, NY), rabbit polyclonal antibody
to heme-oxygenase-1 (HO-1); (8) Frontier Scientific (Logan, UT),
Sn(IV) mesophorphyrin IX dichloride (SnMP); (9) Jackson
ImmunoResearch Labs (West Grove, PA), fluorescein
isothiocyanate-conjugated goat anti-mouse IgG and Cy3-
conjugated goat anti-rabbit IgG secondary antibodies; (10)
Invitrogen (Carlsbad, CA), Dulbecco's modified Eagle's medium
(DMEM), tetramethyl rhodamine methyl ester, goat anti-mouse
beta-lactamase TEM-1 conjugate, fluorocillin green substrate,
dihydroethidium (DHE), 4′,6-diamidino-2-phenylindole (DAPI),
neurobasal media, and B27 supplement; (11) New England
Biolabs (Ipswich, MA), tyramide amplification system; (12)
Peptide International (Louisville, KY), poly-L-lysine; (13) Sigma
Aldrich (St. Louis, MO), carbonyl cyanide m-chlorophenyl
hydrazone, cytosine arabinoside (Ara-C), fetal bovine serum
(FBS), monomethylfumarate (MMF), oligomycin, propidium io-
dide, and PI cocktail; (14) ScyTek Labs (Logan, UT), normal
antibody diluent; (15) Thermo Scientific (Waltham, MA), goat
anti-rabbit horse radish peroxidase (HRP) antibody and goat anti-
mouse HRP antibody, SuperSignal West Dura extended duration
substrate; and (16) Tocris Bioscience (Ellisville, MO), thapsigargin.
The antibody against calpain-cleaved spectrin was a generous gift
from Dr. Robert Siman (The Perelman School of Medicine,
University of Pennsylvania, Philadelphia, PA).
Primary cortical neuroglial cultures Primary rat cortical neu-
roglial, pure neuronal, and pure astrocytic cultures were iso-
lated from embryonic day 17 Sprague Dawley rat pups, with
modifications of protocols previously described (Wilcox et al.
1994). Briefly, the cortical cell suspensions isolated from rat
pups following standard protocols were plated on poly-L-
lysine-coated T25 tissue culture flasks (2×106 cells/flask),
96-well tissue culture plates (0.5×105 cells/well), or glass
coverslips (0.25×106 cells/well). These cultures were main-
tained in neurobasal media with B27 supplement at 37 °Cwith
5%CO2 for the generation of neuroglial cultures, as described
previously (Wang et al. 2010; Akay et al. 2011b; White et al.
2011). Half of the media was replaced with fresh media every
7 days and the experiments were performed at 21 days in vitro
(DIV), at which time the cultures contain approximately 85–
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90 % neurons and 10–15 % astrocytes/glia. For the prepara-
tion of pure neuronal cultures, cultures were treated with
10 μMAra-C 48 h after plating and maintained in neurobasal
media with B27 supplement at 37 °C with 5 % CO2; at 21
DIV, the age at which the experiments were conducted, no
astrocytes are detectable by staining for GFAP. Pure astrocytic
cultures were prepared by initially plating the cortical cell
suspensions in 10 % FBS in DMEM and maintaining at
37 °Cwith 5%CO2 for 7–12 days, after which time astrocytes
constitute more than 90 % of the cultures. These pure astro-
cytic cultures are then replated in T25 flask or poly-L-lysine-
coated glass coverslips in DMEM/10 % FBS and the experi-
ments are conducted 3–5 days after replating.
SIV/pigtail macaque model of HIV CNS disease Juvenile pig-
tailed macaques (Macaca nemestrina) were inoculated with
SIV/DeltaB670 and SIV/17E-Fr, as described previously
(Zink et al. 1999). Beginning 12 days after inoculation, ani-
mals were treated daily with a four ARV drug combination
(cART) until necropsy (range, days 161–175). The treatment
consisted of the NRTI tenofovir (Gilead) at 30 mg/kg subcu-
taneously every day; the PIs saquinavir (Roche) and
atazanavir (Bristol- Myers Squibb) at 205 and 270 mg/kg
orally twice a day, respectively; and the integrase inhibitor
L-870812 (Merck)(Hazuda et al. 2004) at a dose of 10 mg/kg
orally twice a day(Zink et al. 2010). The tenofovir dose was
determined on the basis of previous studies(Tsai et al. 1997),
whereas atazanavir and saquinavir doses were determined by
pharmacokinetic experiments conducted in pig-tailed ma-
caques, and reflected those that resulted in the same area under
the curve as detected in humans treated with atazanavir and
saquinavir (Zink et al. 2010). The dose of the integrase inhib-
itor was based on a previous study conducted in rhesus
macaques(Hazuda et al. 2004).
Rodent model of antiretroviral-induced neurotoxicity All sur-
gical procedures were performed with the approval of the
Institutional Animal Care and Use Committee. Adult male
Sprague Dawley rats were catheterized via jugular vein, as
described previously (Thrivikraman et al. 2002). The drug
cocktail composed of AZT (100 mg kg−1 day−1), ritonavir
(20 mg kg−1 day−1), and saquinavir (25 mg kg−1 day−1) was
administered twice daily for 7 days by continuous intravenous
injection. Each drug dose was based on previously published
studies in rodents (Shibata et al. 2002; Huisman et al. 2003;
Manda et al. 2010; Pistell et al. 2010;Waring et al. 2010; Yang
et al. 2010; du Plooy et al. 2011; Fontes et al. 2011; Lledo-
Garcia et al. 2011; Wagner et al. 2011; Mak et al. 2013;
Reyskens and Essop 2013a, b; Reyskens et al. 2013). The
catheters were flushed with 0.3 ml heparin (50 IU/ml) in PBS
until the end of treatments. At time of euthanasia, preceding
decapitation and tissue harvest, catheter patency was
reverified by response to pre-euthanasia sedation (100 mg/kg
ketamine per 10 mg/kg xylazine). The brains were removed,
the frontal cortex and the hippocampus were dissected on ice,
and the tissue samples were stored at -80 °C until immunoblot
analysis.
Immunofluorescence staining of tissue Tissue slides of
paraffin-embedded tissue sections from hippocampus of male
and female pig-tailed macaques (M. nemestrina) were pre-
pared for immunofluorescent staining, as described previously
(Akay et al. 2011a) . Briefly, glass slides containing paraffin-
embedded sections (10 μm) were heated to 55 °C for at least
30 min, deparaffinized in Histoclear, and rehydrated with
consecutive 100, 95, 90, and 70 % ethanol washes.
Endogenous peroxidase activity was blocked with 3 % H2O2
in methanol and antigen unmasking was achieved with target
retrieval solution at 95 °C for 1 h. Tissue sections were
blocked with 10 % normal goat serum in phosphate-buffered
saline solution (PBS). Mouse monoclonal antibodies to
synaptophysin, MAP2, and rabbit polyclonal antibody to
GFAP were used at empirically defined dilutions
(synaptophysin at 1:500; MAP2 at 1:100; and GFAP at
1:80), and DAPI was used to stain nuclei. The tyramide
amplification system was used to detect synaptophysin.
Slides were mounted in Citifluor AF1, and for each specimen,
five to ten randomly selected areas within the CA1–CA3 layer
of the hippocampus were scanned along the z-axis to create z-
stack images at high magnification (×600) by laser confocal
microscopy on a Biorad Radiance 2100 equipped with Argon,
Green He/Ne, Red Diode, and Blue Diode lasers (Biorad,
Hercules, CA). Post-acquisition analysis was conducted using
MetaMorph 6.0 (Universal Imaging, Downingtown, PA).
Total intensity for synaptophysin, MAP2 and GFAP were
determined by the measurement of integrated pixel intensity
for synaptophysin, MAP2 or GFAP per z-stack image, where
the integrated pixel intensity is defined as total pixel intensity
per image times the area of pixels positive for synaptophysin,
MAP2 or GFAP. Averages are expressed as mean±SEM. All
data was analyzed by Prism 5.0 software (GraphPad Software,
San Diego, CA).
MAP2 cell-based ELISA A MAP2 cell-based ELISA was
performed to quantify neuronal damage/death as previously
described (White et al. 2011). Briefly, primary rat cortical
neuroglial cultures plated in 96-well plates were fixed for
30 min with 4 % paraformaldehyde in 4 % sucrose at the
conclusion of treatments. After blocking for 1 h with 5 %
normal goat serum in PBS, the plates were incubated with
monoclonal MAP2 antibody overnight at 4 °C, followed by
washes with PBS with 0.1 % Tween-20 (PBS-T). The plates
were then incubated for 30 min with goat anti-mouse second-
ary antibody conjugated to beta-lactamase TEM-1 at room
temperature (RT), washed with PBS-T, and incubated in the
dark at RT for 1 h in fluorocillin green substrate. Fluorescence
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intensity was measured using a Fluoroskan Ascent fluorome-
ter plate reader (Thermo Electron, Waltham, MA) with exci-
tation at 485 nm and emission at 527 nm.
Hand counting of MAP2-positive cells As a complementary
method to MAP2 ELISA, neuronal survival was verified by
hand counting of MAP2-positive neurons; 15 μM propidium
iodide was added to primary cortical neuroglial cultures
grown on coverslips 15 min before the end of the treatments.
The coverslips were washed once with PBS and fixed for
30 min with 4 % paraformaldehyde in 4 % sucrose, followed
by blocking and permeabilization in 0.2 %BSA+0.1% Triton
X-100 in PBS for 1 h at RT. The coverslips were then washed
twice with PBS and incubated with anti-MAP2 antibody
(1:100) in normal antibody diluent for 2 h at RT. After two
washes with PBS-T, the coverslips were incubated in a fluo-
rescein isothiocyanate-conjugated goat anti-mouse IgG sec-
ondary antibody (1:200) for 30min at RT. The coverslips were
mounted on slides and alive/dead neurons were hand-counted
based on MAP2 and PI-positive staining using a Nikon
Eclipse E400 fluorescent microscope (Nikon Corp, Tokyo,
Japan) equipped with Olympus DP70 digital camera
(Olympus Corp, Tokyo, Japan). Live cells stain negative for
PI, while dead cells retain it in their nuclei. The number of
surviving MAP2-positive neurons will be positive for MAP2
and negative for PI staining. The percentage of MAP2-
positive cells ± SEM were calculated from blinded counting
of six fields at ×200 in two adjacent vertical columns through
the center of each coverslip, proceeding from top to bottom
and bottom to top. For each condition, three coverslips were
counted from two or more independent experiments.
Quantification of synaptophysin Cultures grown on cover-
slips, as described above, were immunofluorescently stained
for synaptophysin (1:1,000), MAP2 (1:100), and DAPI.
Tyramide amplification was used for the detection of
synaptophysin. For each treatment condition, images of 10
randomly selected areas from three coverslips from three
independent experiments were captured by fluorescence mi-
croscopy. Post-acquisition analysis was performed using NIH
ImageJ program (V 1.36b, Bethesda, MD). Briefly,
synaptophysin-positive puncta were detected by background
subtraction and manual thresholding. The number of
synaptophysin-positive puncta was determined by dividing
the total number of puncta within a dendrite segment by the
length of the segment.
Measurement of reactive oxygen species The superoxide in-
dicator dihydroethidium (DHE, Invitrogen) was used to detect
the presence of reactive oxygen species (ROS) in vitro. 3 μM
DHEwas added to culturemedia 15min prior to conclusion of
treatments. Cells were then washed with PBS, fixed with 4 %
paraformaldehyde in 4 % sucrose at RT for 8 min, and stained
for DAPI. The coverslips were then mounted on slides with
CytoSeal and visualized using fluorescent microscopy, as
described above. Post-acquisition analysis was performed
using MetaMorph to determine the fluorescence intensity of
DHE normalized to the area of DAPI signal.
Immunoblotting Whole cell extracts of rat tissue samples
were prepared by homogenization in ice-cold tissue extraction
buffer (50 mM Tris at pH 7.5, 0.5 M NaCl, 1 % NP-40, 1 %
SDS, 2 mM EDTA, 2 mM EGTA, 5 mM NaF, 0.4 mM
Na3VO4, 1 mM dithiothreitol (DTT), and 1:100 PI cocktail),
followed by centrifugation at 12,000×g at 4 °C for 20 min.
Whole cell extracts of primary rat cortical cultures were pre-
pared with ice-cold cell lysis buffer (50 mM Tris at pH 7.5,
120 mM NaCl, 0.5 % NP-40, 10 mM EDTA, 0.4 mM
Na3VO4, 100 mM DTT, and 1:100 PI cocktail), followed by
centrifugation at 14,000×g at 4 °C for 10 min. The protein
concentrations of the collected supernatants were determined
using the Bradford method and 25–50 μg of protein was
loaded into each lane of a 4–12 % Bis-Tris gradient gel for
separation. A broad range molecular weight ladder was run on
each gel. Subsequent to separation, proteins were transferred
onto PVDF membranes, and blocked in Tris-buffered saline
with 0.1 % Tween-20 (TBS-T) and 5% bovine serum albumin
(BSA) for 1 h at RT. The membranes were incubated with the
primary antibodies in TBS-Twith 5 % BSA at 4 °C overnight,
washed with TBS-T, followed by incubation with correspond-
ing HRP-conjugated secondary antibodies. The membranes
were developed using SuperSignal West Dura extended dura-
tion substrate. Loading controls were obtained by staining the
membranes and the gels with the Biosafe Coomassie Stain for
20 min, followed by destaining with deionized water for
30 min. For densitometric analysis, autographs were scanned
into Adobe Photoshop (Adobe Systems, San Jose, CA) and
regions of interests (ROI) of equal size were determined for
each band. The pixel intensities of ROIs were quantified using
the NIH ImageJ program (V 1.36b, Bethesda, MD). Target
band intensities were normalized to gel and membrane
coomassie stain controls to account for protein degradation
and loading discrepancies, and the normalized target band
intensities were used to quantify fold changes over controls.
Quantitative reverse transcription polymerase chain
reaction The expression of HO-1 and NQO-1 genes in rat
neuroglial cells was quantified by quantitative reverse tran-
scription polymerase chain reaction (qRT-PCR). Custom
TaqMan® Gene Expression Assays were purchased from
Applied Biosystems for the genes: NQO-1
(Rn00566528_m1) and HO-1 (Rn01536933_m1).
Approximately 5 ng cDNA was used per reaction.
StepOne™ Software v2.0 was used to construct the experi-
mental protocol and the qRT-PCR took place in the StepOne
Real-Time PCR System (Applied Biosystems, Carlsbad, CA).
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Data was normalized using both β-actin (Rn00667869_m1)
and 18S (Hs99999901_s1) and was analyzed according to the
ΔΔCT method. All samples were run in triplicate from three
biological replicates.
Statistical analysis All data was analyzed by Prism 5.0 soft-
ware (GraphPad Software, San Diego, CA). Values are
expressed as mean±SEM, and values of p<0.05 were consid-
ered significant for all statistical analyses performed.
Results
Antiretroviral drugs lead to neuronal damage in vivo
cART-induced peripheral neuropathy is well documented
(Power et al. 2009), and it is likely that cART triggers similar
damage to neurons in the CNS. To determine the neurotoxic
potential of cART in the CNS, we assessed the effects of an
ARV regimen on the expression of synaptophysin and MAP2,
indicators of synaptic damage and neuronal loss, respectively,
utilizing post-mortem tissue from a well-characterized SIV/
pigtail macaque model of HIV CNS disease, which was de-
signed to address the efficacy of CNS penetrant antiretroviral
therapy in reducing viral load in the CNS (Zink et al. 2010). In
this study, animals infected with SIVeither received no cARTor
received early cART treatment that included tenofovir (NRTI),
atazanavir (PI), saquinavir (PI), and L-870812a (integrase inhib-
itor) 12 days after the virus inoculation. Without cART, 90 % of
animals develop neurologic disease within 3 months postinocu-
lation (p.i.). By contrast, animals receiving cART do not develop
SIV encephalitis. Rather, they show a rapid reduction in their
plasma and CSF viral load followed by continued suppression
of SIV replication with maintenance of CD4+ Tcell counts until
elective euthanasia around day 160 p.i. Additionally, cART-
treated animals do not exhibit any outward signs of neurological
deficits. Further, our quantitative immunofluorescent analysis of
hippocampal tissue sections revealed reduced astrogliosis in the
hippocampus of SIV-infected, cART-treated animals (SIV(+)/
cART), compared with SIV-infected macaques that did not
receive cART ((SIV(+)/placebo)) (Fig. 1b). However, we ob-
served statistically significant decreases in synaptophysin ex-
pression in the hippocampi of the SIV(+)/cART group, com-
pared with that in either the uninfected or the SIV(+)/placebo
group (Fig. 1a, d). In addition, examination of the expression of
a secondmarker of synaptodendritic integrity, calmodulin kinase
II (CaMKII), by immunoblotting showed that CaMKII levels
were significantly lower in the frontal cortex in the SIV(+)/
cART macaques than in their SIV(+)/placebo counterparts
(Fig. 1e, f). CaMKII is highly expressed in neurons of macaque
hippocampus and frontal cortex, whereas its expression in other
cell types, including microglia, infiltrating macrophages, and
multinucleated giant cells, is minimal; thus, the differences in
CaMKII expression in frontal cortex of the animals from our
experimental groups are neuron specific (Gupta et al. 2010). Our
results demonstrate synaptic injury in the presence of cART
despite effective control of SIV replication in the periphery
and CNS. Interestingly, we did not observe changes in MAP2
fluorescence in the hippocampus of infected and/or cART-
treated animals compared with untreated/uninfected animals
(Fig. 1a, c).
As studies of uninfected, cART-treated macaques have not
been performed to determine the contribution of cART to
neuronal damage independent of SIV infection, we adminis-
tered combinations of ARVs intravenously to adult rats. In
patients, initial cART usually includes two nucleoside/NRTIs
in combination with a nNRTI or with a PI boosted with a low
dose of a second PI, ritonavir (Rit). Thus, we used zidovudine
(AZT), an NRTI, along with two PIs, saquinavir (Saq) and Rit,
at doses based on previously published pharmacokinetic stud-
ies of these ARVs (Busidan and Dow-Edwards 1999;
Kageyama et al. 2005; Pistell et al. 2010). In agreement with
previous studies (Waring et al. 2010), the animals showed no
overt signs of distress during the course of the treatment.
However, via immunoblotting, we observed decreases in hip-
pocampal synaptophysin expression in cART-treated rats
compared with vehicle-treated rats (Fig. 1g), complementing
our findings of synaptic damage in SIV(+)/cART macaques
and further supporting a role for ARV-associated neuronal
injury in the CNS. Of note, we also detected decreases in
MAP2 levels in the cART-treated rat hippocampus (Fig. 1g),
which likely reflects the acute drug toxicity in this treatment
paradigm, compared to the subtler synaptic injury observed in
the cART-treated macaque brain.
Antiretroviral compounds in therapeutically relevant
combinations are neurotoxic in vitro
The only primary neural cell-type previously studied for ARV
toxicity was dorsal root ganglia neurons in models of periph-
eral neuropathy (Werth et al. 1994). Here, to expand our
studies on ARV neurotoxicity in the CNS, we used primary
rat cortical neuroglial cultures aged 21 DIV (O'Donnell et al.
2006; Wang et al. 2007; White et al. 2011). We first evaluated
the neuronal viability in response to increasing concentrations
of AZT, Rit, or Saq. We based the range of doses on reported
plasma and CSF levels of ARVs (Wynn et al. 2002;
Anthonypillai et al. 2004). Importantly, animal studies predict
brain parenchymal levels to be equal to or greater than CSF
levels (Anthonypillai et al. 2004; Anderson and Rower 2010).
At 48 h posttreatment with individual ARVs, Rit and Saq both
led to dose-dependent decreases in MAP2-positive cells, as
determined via hand counting (Fig. 2a, b, respectively). These
results were confirmed with a cell-based MAP2 ELISA,
which accurately reflects neuronal numbers, as well as
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neuronal damage (Fig. 2d, e) (White et al. 2011). Furthermore,
neuronal damage and death induced by Rit and Saq was time
dependent, as seen in Fig. 2g, where the primary cortical
cultures were exposed to individual ARVs for up to 8 days.
Additionally, both Rit and Saq led to dose-dependent de-
creases in synaptophysin expression after 16 h of treatment,
well before the loss of MAP2-positive cells occurred
(Fig. 2h, i). However, AZT did not lead to decreases in
MAP2-positive cells, MAP2 fluorescence, or synaptophysin
expression (Fig. 2c, f, and data not shown, respectively). Next,
we treated primary cortical cultures with drug combinations
that included AZT, Rit, and Saq, alone or in combinations, for
48 h, to assess acute neurotoxicity. As seen in Fig. 2j, k,
combination treatments that included Rit induced statistically
significant neuronal damage/death, which were preceded by
loss of synaptophysin detected at 16 h posttreatment (Fig. 2l).
Additionally, we observed similar levels of neuronal damage
in cortical cultures treated with a combination of d4T, Rit, and
Saq (not shown). However, as d4T is no longer prescribed in
most developed countries and the AZT/Rit/Saq combination
reflects the first considered/prescribed combination in initial
treatment plans, we focused on AZT/Rit/Saq combination
treatments for further experiments. Next, we determined that
treatment with either Rit or Saq, alone or in combination with
AZT, lead to the activation of the Ca2+-activated death prote-
ase, calpain, as evidenced by the increase of calpain-cleaved
spectrin observed in these cultures (Fig. 3). Interestingly, none
of the treatment combinations caused increases in the cleaved,
and therefore active, form of caspase-3 (Fig. 3), suggesting
that neuronal death observed in our model may be a necrotic
cell death rather than an apoptotic cell death. Together the
findings presented here suggest that combination ARV treat-
ments that include PIs are toxic to cortical neurons in vitro.
Combination antiretroviral drug treatments induce oxidative
stress in neurons
An extensive number of studies have linked ARVs, especially
PIs, to oxidative stress (Touzet and Philips 2010). To deter-
mine whether neurons undergo oxidative stress when exposed
Fig. 1 Antiretroviral drugs induce neuronal damage in vivo. a–dForma-
lin-fixed, paraffin-embedded tissue sections from hippocampus of pig-
tailed macaques that were either uninfected (n=6), SIV infected but not
cART treated (n=7), or SIV infected and treated with cART (tenofovir,
atazanavir, saquinavir, and L-870812a; n=4) were prepared for immuno-
fluorescent analysis and were triple labeled for MAP2 (red),
synaptophysin (green), and GFAP. Sections were visualized by laser
confocal microscopy and images were quantified for MAP2,
synaptophysin and GFAP expression. aRepresentative composite images
of two cases per group which were stained with MAP2 and
synaptophysin are shown. Scale bar=30 μm. b Quantification shows
the resolution of GFAP immunoreactivity in SIV(+)/cART group, com-
pared with SIV(+)/placebo group (one-way ANOVA, *p<0.05). No
changes were observed in MAP2 expression between groups (c), but
there were statistically significant decreases in synaptophysin
immunoreactivity (d) in SIV(+)/cART group, as compared with SIV(+)/
untreated and uninfected groups (one-way ANOVA, *p<0.05, ns not
significant). e, f Fresh-frozen tissue sections from the frontal cortex of
pig-tailed macaques that were either uninfected (n=3), SIV infected but
not cART treated (n=6), or SIV infected and cART treated (n=6) were
used for standard protein extraction and subsequent immunoblotting for
the expression of CaMKII. Actin was used as a loading control. A
representative immunoblot is shown. Quantification shows statistically
significant decreases in CaMKII in the cART-treated group, as compared
with the uninfected group or the SIV(+)/untreated group (one-way
ANOVA, *p<0.05). g Whole cell lysates prepared from hippocampus
of rats treated for 7 days with AZT/Rit/Saq (n=4) or vehicle (n=2) were
immunoblotted for synaptophysin and MAP2. A band from the
coomassie blue staining is included to control for equal loading and
protein degradation
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to ARVs, we used dihydroethidium (DHE) as a marker for the
presence of ROS (Rodriguez-Pallares et al. 2009). We includ-
ed tert-butyl hydroperoxide, an organic pro-oxidant, at
100 μM, as a positive control. As seen in Fig. 4a and quanti-
fied in Fig. 4d, Rit/Saq and AZT/Rit/Saq combination drug
treatments for 6 h lead to ROS accumulation in cortical
cultures, whereas ROS levels in vehicle-treated cultures were
comparable to those in untreated cultures.
The cortical cultures generated for our studies contain
85–90 % neurons and 10–15 % astrocytes (Fig. 4b); thus,
we also determined the presence of ROS in pure neuronal
and pure astrocytic cultures exposed to individual ARVs.
As seen in Fig. 4c and quantified in Fig. 4e, Rit led to an
early and sustained ROS production in pure neuronal
cultures, whereas Saq-induced ROS accumulation oc-
curred 24 h after treatment. The transient ROS accumula-
tion induced by AZT was resolved at 24 h posttreatment.
Conversely, in pure astrocytic cultures, none of the three
ARVs examined induced an appreciable sustained ROS
generation, and only Rit caused a transitory ROS accu-
mulation (Fig. 5a, b). These data further suggest that the
ARV-induced ROS production observed in primary corti-
cal neuroglial cultures are occurring in neuronal cell
populations.
Endogenous antioxidant response activation by combination
antiretroviral drugs
Oxidative stress in cells triggers the transcriptional induc-
tion of oxidative stress responsive genes through the acti-
vation of the endogenous antioxidant response element in
their promoter regions (Chen and Kong 2004). Thus, we
determined the effect of ARVs on two such genes, NQO-1
and HO-1. By qRT-PCR, we observed increased mRNA
levels of both NQO-1 and HO-1 in cultures treated with any
of the tested combinations of ARVs, when compared with
the levels in untreated cultures (Fig. 6a, b, respectively),
with the most striking increases observed in Rit/Saq-treated
cultures. To determine whether the changes in the mRNA
levels were reflected in protein levels, we used immuno-
blotting to examine protein levels of NQO-1 and HO-1.
While we observed increases in NQO-1 and HO-1 protein
levels at 16 h (Fig. 6c), the changes were more robust in
cultures treated for 48 h (Fig. 6d). Further, in vivo, we
detected increased levels of HO-1 protein in hippocampal
lysates from cART-treated rats (Fig. 6e, f). Interestingly,
NQO-1 levels were not increased in cART-treated rat hip-
pocampus (Fig. 6e). Of note, we did not observe an antiox-
idant response in ARV-treated pure astrocytic cultures
(Fig. 5c–e). These data collectively suggest an activation
of HO-1, as part of the endogenous antioxidant response,
following ARV treatments in neurons.
Monomethyl fumarate protects against ROS generation
and induces activation of the endogenous antioxidant
response
NQO-1 and HO-1 are targets of the fumaric acid ester, di-
methyl fumarate (DMF), and of its hydrolyzed and active
metabolite, MMF (Linker et al. 2011). Our recent study
(Cross et al. 2011) has shown that DMF and MMF reduce
neurotoxin release from HIV-infected macrophages through
induction of HO-1. We reasoned that augmented or earlier
induction of NQO-1 and HO-1 in neurons by pretreatment
with the active metabolite, MMF, would provide protection in
our in vitro model of ARV-induced neurotoxicity through an
antioxidant effect. We first determined that MMF at 30–
100 μM was not toxic in neuronal cultures, as determined
by MAP2 ELISA (data not shown). Next, we preincubated
primary cortical cultures with 100 μM MMF for 30 min
before adding either Rit/Saq or AZT/Rit/Saq. Preincubation
with MMF blocked ROS generation induced by ARV treat-
ments lasting 6 (Fig. 7a), 16, and 48 h (data not shown).
Quantification showed ROS levels in cultures preincubated
with MMF to be comparable to those detected in untreated
and vehicle-treated cultures (Fig. 7b). Furthermore, we ob-
served an early increase in HO-1 protein levels at 4 h in
cultures preincubated with MMF, whether or not pretreatment
was followed by ARV treatment (Fig. 7c). This trend was
sustained at 16 h after combination ARV treatment, as well.
Next, we determined whether augmenting the endogenous
antioxidant response by MMF blocks MAP2 loss induced
by combination ARV treatments. As detected by the cell-
based MAP2 ELISA, MMF blocked neuronal damage/death
in cultures treated with Rit/Saq and AZT/Rit/Saq for 72 h
(Fig. 7d). Finally, pretreatment of the cultures with an HO-1
inhibitor, SnMP (Zhao et al. 2004), reversed the MMF-
induced decreases in ROS accumulation (Fig. 7e), suggesting
that MMF protection occurs through its augmentation of HO-
1 expression.
Discussion
Virus-related factors, such as resistant virus species and per-
sistent viral DNA in the CNS, may contribute to the persis-
tence of HAND in the post-cART era. One recent focus in
HIV neurovirology is the development of ARVs with greater
CNS penetrance (Letendre et al. 2008; Marra et al. 2009;
Tozzi et al. 2009; Edén et al. 2010; Heaton et al. 2010;
Garvey et al. 2011; Smurzynski et al. 2011). However, poten-
tial ARV toxicity in the CNS remains largely unexplored. Our
study supports a possible contribution of the ARVs them-
selves to neuronal and synaptic damage observed in patients
with HAND.
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Fig. 2 Therapeutically relevant combination antiretroviral drug treat-
ments are neurotoxic in vitro. a–c Primary rat cortical neuroglial
cultures aged 21 days in vitro (DIV) on coverslips were exposed to
Rit (a), Saq (b), or AZT (c) at increasing doses for 48 h, followed by
hand counting for MAP2-positive cells (n=3; vehicle, 0.04 % DMSO;
* p<0.05, one-way ANOVA with post-hoc Newman–Keuls). d–f
21DIV primary neuroglial cultures grown in 96-well plates were
treated with increasing doses of Rit (d), Saq (e), or AZT (f) for 48 h,
followed byMAP2 cell-based ELISA (n=2; vehicle, 0.04 %DMSO; *
p<0.05, one-way ANOVAwith post-hoc Newman–Keuls). g Primary
neuroglial cultures were treated with AZT (25 μM), Rit (10 μM), or
Saq (1 μM) at day zero. Ninety percent of the media was changed with
conditioned media supplemented with a fresh drug stock every 2 days,
and cultures were analyzed by MAP2 cell-based ELISA at days 4 and
8 (n=2; vehicle, 0.04 % DMSO; * p<0.05, one-way ANOVA with
post-hoc Newman–Keuls). h, i Cultures grown on coverslips were
exposed to the indicated treatments and synaptophysin-positive
puncta were determined (n=3; vehicle, 0.04 % DMSO; * p<0.05,
one-way ANOVA with post-hoc Newman–Keuls). j, k Primary neu-
roglial cultures were exposed to the indicated drug combinations
(AZT, 25 μm; Rit, 10 μm; Saq, 1 μm) for 48 h, followed by hand
counting for MAP2-positive cells (j) or MAP2 cell-based ELISA (k)
(n=2; vehicle,: 0.04 % DMSO; * p<0.05; # p<0.01, one-way ANOVA
with post-hoc Newman–Keuls). l Primary neuroglial cultures that
were exposed to the indicated drug combinations (AZT, 25 μm; Rit,
10 μm; Saq, 1 μm) for 16 h were analyzed for synaptophysin-positive
puncta (n=2; vehicle, 0.04 % DMSO; * p<0.05, one-way ANOVA
with post-hoc Newman–Keuls)
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In this study, we show cART-induced synaptophysin loss,
indicative of synaptic injury in two animal models. In our first
model, in an in vivo model of SIV-infected pig-tailed ma-
caques, we report decreased synaptophysin and CaMKII
levels in the SIV(+)/cART group compared with uninfected
or SIV(+)/placebo groups, indicating synaptodendritic dam-
age. Interestingly, MAP2 levels did not change significantly
across groups, which may be because of the relatively short
duration of infection in this retrospective study cohort. While
these data demonstrate potential effects of cART drugs in the
presence of viral infection, there are three variables to consider
in interpretation of these findings: (1) the time to euthanasia
from the start of the experiments is different between SIV(+)/
placebo and SIV(+)/cART groups, (2) persistent viral DNA in
the CNS of SIV(+)/cART group, and (3) the lack of SIV(-)/
cART group. It is not yet known whether brain SIV DNA is
replication competent. As we utilized post-mortem samples
obtained from a cohort of macaques enrolled in a previous
study addressing the efficacy of CNS penetrant cART in
reducing viral loads in the CNS, further experiments that
include an additional control group receiving cART but not
inoculation with SIV will be instrumental to more clearly
determine the contribution of viral DNA and cART to synap-
tic damage in this model.
In the second in vivo model presented here, adult rats
received a therapeutically relevant combination of ARVs
(NRTI+PI+Rit boost). In the small number of studies where
pharmacokinetics and effects of ARVs in the CNS were
examined, pathological read-outs of neuronal damage, such
as MAP2 or synaptophysin loss, were not determined
(Huisman et al. 2003; Anthonypillai et al. 2004;
Anthonypillai et al. 2006). Synaptic injury is a known indica-
tor of neuronal damage and dysfunction in various neurode-
generative diseases, including HAND (Gupta et al. 2010) and
synaptodendritic injury persists in HIV-infected individuals in
the post-cART era (Xu and Ikezu 2009). We observed de-
creases in synaptophysin and MAP2 protein levels in the
hippocampus in response to ARVadministration over 7 days.
Thus, our model demonstrates that ARV-associated neurotox-
icity warrants consideration in developing therapeutic regi-
mens for HIV-infected patients.
We also show that the PIs, Rit and Saq, alone or in combi-
nations with the NRTI, AZT, induce oxidative stress, and
neuronal damage/death in primary cultures at clinically rele-
vant doses. Previous studies examined ARV-induced toxicity
in cell lines, and Robertson et al. have provided the first
evidence for ARV-induced neurotoxicity in primary rat neu-
rons (Robertson et al. 2012). Here, we provide further evi-
dence that PI-induced oxidative stress and neuronal death in
primary neurons can be blocked by the activation of the
endogenous antioxidant response. Interestingly, in our exper-
imental paradigm, the NRTI, AZT, neither induced neuronal
damage/death by itself, nor augmented PI-induced damage/
death when used in combination. We observed similar effects
from a combination using another NRTI, stavudine (d4T; not
shown). In agreement with our observations, a previous study
presented similar findings, specifically that neither AZT nor
d4T inhibited cell growth or neurite regeneration in PC-12
cells after long-term drug exposure (Cui et al. 1997). It should
be noted that NRTIs are unequivocally tied to peripheral
neuropathy, where the underlying pathology is mitochondrial
toxicity and oxidative stress. However, NRTIs affect only
certain cell populations, as they are formulated as pro-drugs
and, to become active, need to be phosphorylated by two
kinases, thymidine kinase 1 and 2 (TK1 and TK2), and the
expression of the cytoplasmic TK1 is cell cycle dependent
(Bazzoli et al. 2010). Thus, in our model utilized to study post-
mitotic neurons, AZT is most likely not converted to its active
form, and thus does not contribute to neuronal damage/death.
It is of note that our in vitro model of ARV-induced neurotox-
icity utilized primary neuroglial cultures rather than cell lines.
Primary cells are untransformed, and therefore more accurate-
ly reflect and predict ARV-associated effects occurring in the
brains of patients on cART than would immortalized cell
lines. The molecular pathways we investigated in this study
are highly conserved from yeast to human cells; thus, the
results obtained here in cells of rodent origin are likely con-
served in human cells as well.
The drug concentrations used in this study are based on the
plasma and CSF levels reported by various in vitro and in vivo
studies(Huisman et al. 2003). As reported in such studies,
AZT can be detected in the CSF at concentrations that are
similar to those measured in the plasma (Wynn et al. 2002).
Contrarily, as backed by various in vitro and in vivo studies
(Wynn et al. 2002), both Rit and Saq are predicted to have
limited CNS penetrance due to the strong tendency of these
drugs to bind plasma protein because of their lipophilic nature
Fig. 3 Activation of Calpain in antiretroviral drug-treated neurons.
Whole cell lysates were prepared from neuroglial cultures treated with
the indicated single or combination drugs (AZT, 25 μm; Rit, 10 μm; Saq,
1 μm), or with Thapsigargin (1 μM) as a positive control, for 48 h.
Calpain activation was assessed using an antibody to detect the accumu-
lation of calpain-cleaved spectrin and an antibody raised against the
cleaved and active form of caspase-3 was used for detection of caspase
activity. A band revealed by coomassie staining of the gel was used as a
loading control (n=2; vehicle, 0.04 % DMSO)
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and pharmacokinetic properties. However, a comprehensive
study conducted in an in situ guinea pig model suggests that
Rit can achieve high concentrations in choroid plexus and
parenchyma through diffusion via the choroid plexus; in fact,
the levels of Rit were comparable to levels measured in
plasma (Anthonypillai et al. 2004). Furthermore, the study
showed that, surprisingly, the CSF levels of Rit were lower
than the levels measured in the choroid plexus and the paren-
chymal compartments. Thus, the authors concluded that CSF
concentrations of Rit may not necessarily reflect the
Fig. 4 Combination
antiretroviral drug treatments
induce oxidative stress in
neurons. a, dCortical neuroglial
cultures grown on coverslips were
treated for 6 h with the indicated
drugs (AZT, 25 μm; Rit, 10 μm;
Saq, 1 μm) and the presence of
ROS was detected by DHE
staining (red fluorescence). a The
images were captured with
epifluorescent microscopy with
uniform settings. dQuantification
of DHE fluorescence was
generated by measurement of
DHE pixel intensity per DAPI
area (n=3; *p<0.05; #p<0.01,
one-way ANOVA, post-hoc
Newman–Keuls). bCortical
neuroglial cultures grown on
coverslips for 21 days and
exposed to the indicated
treatments (AZT, 25 μm; Rit,
10 μm; Saq, 1 μm) were
immunofluorescently labeled for
MAP2 (green) and GFAP (red).
Note that the cultures are enriched
for neurons; c 21 DIV pure
cortical neuronal cultures grown
on coverslips were treated with
AZT (25 μm), Rit (10 μm), or
Saq (1 μm) for 2, 12, or 24 h. The
presence of ROS was detected by
DHE staining (red fluorescence)
and MAP2 was used to stain
neurons (green fluorescence). e
The images captured with
confocal microscopy with
uniform settings were analyzed
for DHE pixel intensity per DAPI
area (n=3; *p<0.05, one-way
ANOVA, post-hoc Newman–
Keuls)
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parenchymal levels, which are indeed a better indicator of
effective drug levels in the CNS. Rit and Saq concentrations
in our experiments fall well within plasma ranges reported in
patients receiving cART.
Evidence of oxidative stress has long been associated
with the most severe forms of HAND (Ngondi et al. 2006;
Mielke et al. 2010). Interestingly, despite systemic control
of viral replication in cART-treated patients, markers of
oxidative stress, such as elevated levels of lipid and pro-
tein oxidation, are still detectable in the brains of these
individuals (Ances et al. 2008). Of note, oxidative stress
is one of the underlying mechanisms involved in NRTI
and PI-induced toxicity in the periphery. Our data suggest
that the sustained ROS accumulation in neurons due to
prolonged exposure to ARVs might induce the oxidative
stress associated with cART-induced toxicity in the CNS,
leading to the observed changes in synaptophysin levels
and the subsequent neuronal death.
Our data also suggest that astrocytes do not show neither
ROS accumulation nor the endogenous antioxidant response
in vitro. We also observe that astrogliosis in SIV-infected
animals is resolved in cART-treated animals. While these
findings suggest that astrocytes may not be highly impacted
by ARVs in the short term, it is possible that prolonged
exposure to ARVs might overwhelm astrocytes, which help
buffer ROS accumulation in neurons under normal conditions,
precipitating further neuronal damage.
We further show that the ARV drug-induced effects ob-
served in this study can be blocked by MMF via activation of
an endogenous antioxidant response. Cells respond to oxida-
tive stress by activating the transcription of a subset of genes
in an effort to clear excess ROS within the cell. Among these
genes are NQO-1 and HO-1 (Chen and Kong 2004). Here, we
show increased levels of NQO-1 and HO-1 mRNA and pro-
tein in ARV-treated neuronal cultures. Additionally, pretreat-
ment of cultures with MMF led to further increases in HO-1
Fig. 5 Antiretroviral drugs do
not induce an endogenous
antioxidant response in
astrocytes. a Pure astrocytic
cultures grown on coverslips were
treated with AZT (25 μm), Rit
(10 μm), or Saq (1 μm) for 2, 12,
or 24 h. The accumulation of
ROS was detected by DHE
staining (red fluorescence) and
GFAP was used to label
astrocytes (green fluorescence). b
The images captured with
confocal microscopy with
uniform settings were analyzed
for DHE pixel intensity per DAPI
area (n=3; * p<0.05, One-Way
ANOVA, post-hoc Newman–
Keuls). c–eWhole cell lysates
from pure astrocytic cultures
treated with the indicated drugs
(AZT, 25 μm; Rit, 10 μm; Saq,
1 μm) for 16 h were
immunoblotted for HO-1 and
NQO-1. Representative blots
from three independent
experiments are shown in (c).
Coomassie staining of gels were
used as loading controls and fold
changes over untreated lysates
were determined. The
quantification of HO-1 and NQO-
1 band intensities from three
independent experiments is
shown in (d) and (e) (n=3;
*p<0.05, one-way ANOVA, post-
hoc Newman–Keuls)
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protein levels in ARV-treated cultures and provided protec-
tion against ARV-induced toxicity. Finally, our finding that
the protection provided by MMF is reversed with chemical
inhibition of HO-1 further provides evidence that ARV
toxicity is mediated via induction of oxidative stress. The
neuronal damage and death that occurs despite the cellular
initiation of the endogenous antioxidant response following
exposure to ARVs suggests that this response may be in-
sufficient or too delayed to protect cultures from ARV
toxicity. In support of this explanation, we observed that
MMF-mediated augmentation of antioxidant responses is
strongly protective against the neurotoxic effects of ARVs.
Further studies using this in vitro model are warranted to
determine whether other clinically relevant ARV drug com-
binations induce neurotoxicity and, if so, to establish
whether similar pathways are involved.
DMF, a psoriasis treatment used in Europe since 1994, is
currently being tested as a disease-modifying agent for multi-
ple sclerosis (MS) (Anonymous 2011; Krieger 2011; Linker
et al. 2011). MMF is the active DMF metabolite in vivo. Our
report is the first to show MMF as a neuroprotectant against
ARV-induced damage. Data from studies inMS patients show
that DMF/MMF has good tolerability, can cross the BBB
efficiently, and has relatively few and minor side effects.
Furthermore, we have recently shown that DMF suppresses
HIV replication, induces the antioxidant response in
macrophaghes, and blocks neurotoxin release from macro-
phages (Cross et al. 2011). Overall, our findings make this
immunomodulatory and antioxidant agent a good potential
adjunctive therapeutic for use in HAND.
One of the paradoxical outcomes of cART is the persis-




antioxidant response in primary
neuroglial cultures. a, bCortical
neuroglial cultures were exposed
to the indicated treatments (AZT,
25 μm; Rit, 10 μm; Saq, 1 μm)
for 6 h to determine changes in
NQO-1 (a) and HO-1 (b) mRNA
levels. A representative of three
experiments is shown. Actin was
used as internal control and fold
changes were determined by the
ΔΔCT method (*p<0.0001, one-
way ANOVA, post-hoc
Newman–Keuls). c, dWhole cell
lysates from cortical neuroglial
cultures treated with the indicated
drug combinations (AZT, 25 μm;
Rit, 10 μm; Saq, 1 μm) for 16 and
48 h were immunoblotted for
NQO-1 (c) and HO-1 (d).
Representative blots from three
independent experiments are
shown. Coomassie staining of
gels were used as loading controls
and fold changes over untreated
lysates are indicated below each
band of interest. e, fWhole cell
lysates prepared from
hippocampus of rats treated for
7 days with AZT/Rit/Saq (n=4) or
vehicle (n=2) were
immunoblotted for HO-1 and
NQO-1 (e) and fold change in
HO-1 protein levels in the cART
group compared with the vehicle
group is shown (f) (*p<0.05,
Student's t test)
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there is a shift from overt dementia to subtler neurocognitive
impairments. Based on data presented here, we propose that
different mechanisms by which HIV infection and cART
induce neuronal damage underlie the changing neuropatholo-
gy of HAND. Extensive studies have shown that during
lentiviral infection, viral proteins and soluble factors secreted
by infected cells lead to neuronal and synaptic damage via
several direct as well as indirect mechanisms involving sev-
eral cell types, including astrocytes. However, our data sug-
gest that cART-mediated synaptic damage may involve direct
mechanisms occurring specifically in neurons, such as oxida-
tive stress, and that neurons, and not astrocytes, are the pri-
mary targets of cART-mediated damage in the CNS.
It is most likely that chronic exposure to cART regimens
including neurotoxic ARVs over many years is associated
with a slower, nonetheless insidious changes including
synaptic damage in the absence of neuronal loss, and
these neuronal perturbations may contribute to, and may
even precipitate, some of the clinical and pathological
changes observed in the chronic course of HAND in the
cART era. While detrimental, such slow damage also
suggests that alterations in cART regimens to include
ARVs with low neurotoxicity profiles, such as NRTIs or
nNRTIs may halt synaptic damage, and provide a point
where previous damage may be reversed, either due to the
withdrawal of the toxic drug, or with the help of an
adjuvant, such as fumaric acid esters. Future studies, first
in primates, then in humans, will be crucial to explore the
specific impact of treatment interruption on recovery from
cART-mediated neuronal damage and to determine the
eddicacy of potential adjunctive therapies necessary to
mitigate the side effects of cART in the CNS.
Fig. 7 MMF induces activation of a cellular antioxidant response and
blocks neuronal damage/death. a In the absence (top) or presence (bottom)
of MMF (100 μM), 21 DIV rat neuroglial cultures on coverslips were
treated for 6 h with Rit/Saq or AZT/Rit/Saq (AZT, 25 μm; Rit, 10 μm;
Saq, 1 μm) or were left untreated. ROS generation was detected by DHE
staining (red fluorescence). bQuantification of nuclear DHE was done as
described above (n=3; *p<0.01, one-way ANOVAwith post-hoc New-
man–Keuls). cWhole cell lysates of cultures exposed to Rit/Saq or AZT/
Rit/Saq treatments (AZT, 25 μm; Rit, 10 μm; Saq, 1 μm) in the absence
or presence ofMMF (100μM) for 4 or 16 h were immunoblotted for HO-
1. A representative blot from three independent experiments is shown. A
coomassie band from the gel was used as loading control. Quantification
of band intensities is shown under each corresponding lane. d Primary
cortical neuroglial cultures were either pretreated with MMF (100 μM)
for 30 min or received no pretreatment; cultures were then treated with
Rit/Saq or AZT/Rit/Saq (AZT, 25 μm; Rit, 10 μm; Saq, 1 μm) for 72 h to
assess neuronal damage/death by MAP2 ELISA (n=3; vehicle=0.04 %
DMSO; *p<0.05 vs. untreated; @p<0.05 vs. Rit/Saq; #p<0.05 vs. AZT/
Rit/Saq, one-way ANOVA with post-hoc Newman–Keuls). e Primary
cortical neuroglial cultures were preincubated with SnMP (20 μM) and/
or MMF (100 μM) for 30 min before the addition of the indicated
antiretroviral drugs (AZT, 25 μm; Rit, 10 μm; Saq, 1 μm) and were
assessed for nuclear DHE accumulation at 16 (n=3; *p<0.01 vs. untreat-
ed; **p<0.05 vs. untreated; @p<0.01 vs. Rit/Saq; #p<0.05 vs. AZT/Rit/
Saq, one-way ANOVAwith post-hoc Newman–Keuls)
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